MedTrace Logo

Clinical Study of Intra Articular Injection of Catholic MASTER Cell (Bone Marrow Derived Mesenchymal Stem Cell) in Knee Osteoarthritis

NCT04240873 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-01-27

No results posted yet for this study

Summary

1. objective

\- safety and efficacy evalaution of MASTER cells injected into knee of patients with osteoarthritis
2. background

* osteoarthritis

* Osteoarthritis is severe and intractable musculoskeletal disease that eventually leads to joint failure and pain due to inflammation and joint injury.
* OA is one of the most prevalent diseases. The prevalence increases with age, but overuse and trauma can result in OA in young population as well.
* Injured cartilage can not be regenerated spontaneously, untreated injured cartilage eventually leads to osteoarthritis. Surgical treatment may repair the damage but the reparied cartilage may turn out to be fibrocartilage rather than hyaline cartilage.
* Curent treatment

* medical therapy: medication for symptom relief, together with exercise. Medications include NSAIDS visco-supplement.
* surgical therapy: total knee replacement arthroplasty
* to overcome such limitations, cell therapy such as stem cell/ chondrocyte injection is being investigated
3. Hypothesis

\- Intra articular injection of MASTER cells will show safety and efficacy in terms of pain and functional improvement.
4. Protocol 1) deisgn : Injection of MASTER cell 1X 10\^8 cells/2cc (experimental arm) or 2cc saline (placebo arm) into knee of patients with osteoarthritis 2) outcomes

* primary outcome : safety evaluation(adverse event)
* secondary outcomes : check on 1,2,3,6,9,12 months, atient reported outcome (WOMAC, KOOS, IKDC, pain VAS) 3,12 months SF-36, knee MRI score, serum cytokine, bone turnover marker 12 months x-ray 3) Disease
* osteoarthritis

4\) Subjects
1. inclusion : age 20-80yrs, diagnosed with OA according to ACR criteria for knee OA, baseline pain VAS equal or more than 50mm
2. exclusion: lower extremities surgery within 6months or planned surgery, concommitant systemic rheumatic diseases that can affect the results of the trial, steroid intraarticular inejction into the index knee within 3months, clinicallly meaningful abnormal lab tests (liver function, kidney function)

5\) evaluation
* primary outome : compare the number and proportion of of adverse event and lab test abnormalities between the two arms
* secondary outome

1. change of 100mm pain VAS
2. change of Western Ontario and McMAster Universities Osteoarthritis (WOMAC) pain VAS, IKDC, KOOS total score
3. change WOMAC sub scale, IKDC, KOOS
4. chagne of KHAQ
5. change of MRI indices
6. change of x-ray( joins space narrowing)
7. change of serum ESR/CRP, CTX-II

Conditions

  • Osteoarthritis, Knee

Interventions

BIOLOGICAL

Catholic MASTER cell

Injection of CATHOLIC MASTER cells 1 x 10\^8 cells/DMEM 5cc into knee of patents with osteoarthritis

OTHER

Saline

Injection of saline 5cc into knee of patents with osteoarthritis

Sponsors & Collaborators

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Ji Hyeon Ju, MD, PhD · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2021-03-31
Completion
2022-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04240873 on ClinicalTrials.gov